Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$8.37
$8.37
$2.66
$8.55
$401.26M0.522.97 million shsN/A
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$18.65
-0.3%
$19.54
$7.48
$29.82
$334.39M1.26210,465 shs217,483 shs
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$1.03
$1.01
$0.32
$1.57
$211.41M2.151.93 million shsN/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
$16.24
$16.23
$7.15
$16.26
$531.75M2.36114,469 shsN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$0.65
+7.9%
$0.56
$0.38
$8.98
$55.59M1.76615,883 shs1.03 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
-0.11%+0.05%-3.06%+2.75%+122.47%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
0.00%0.00%0.00%0.00%0.00%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
+13.37%+0.50%+20.03%+37.09%-92.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
2.8654 of 5 stars
3.20.00.00.01.61.73.1
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.4771 of 5 stars
0.00.00.04.70.60.00.6
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
3.9397 of 5 stars
3.11.00.04.72.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
0.00
N/AN/AN/A
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
2.40
Hold$36.4095.17% Upside
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00
N/AN/AN/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
0.00
N/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.20
Hold$8.001,134.00% Upside

Current Analyst Ratings Breakdown

Latest RIGL, CNCE, UROV, VRCA, and SPPI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/7/2025
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.00
4/9/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/8/2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$32.58M12.32N/AN/A$3.24 per share2.58
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$179.28M1.86$1.08 per share17.34$0.19 per share98.16
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$10.11M20.91N/AN/A$0.15 per share6.87
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/AN/AN/AN/A($1.90) per shareN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$7.57M7.92N/AN/A($0.11) per share-5.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/A
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$17.49M$2.079.0117.76N/A18.31%-655.26%24.47%8/5/2025 (Estimated)
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
-$146.74M-$4.71N/AN/AN/AN/AN/A-162.90%N/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$76.58M-$1.20N/AN/AN/AN/AN/A-145.63%8/13/2025 (Estimated)

Latest RIGL, CNCE, UROV, VRCA, and SPPI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.14-$0.10+$0.04-$0.10$2.53 million$3.44 million
5/6/2025Q1 2025
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
$0.14$0.63+$0.49$0.63$43.87 million$53.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/A
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
N/AN/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/AN/AN/AN/AN/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/A
9.03
9.03
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
2.42
2.20
2.13
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/A
2.71
2.38
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/A
2.91
2.91
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/A
1.34
1.26
CompanyEmployeesShares OutstandingFree FloatOptionable
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
6447.94 million42.51 millionOptionable
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
16017.87 million16.18 millionOptionable
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
86205.25 million199.70 millionOptionable
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
7032.74 millionN/ANot Optionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4092.49 million42.55 millionOptionable

Recent News About These Companies

Verrica Shareholder Sues Board Over FDA Approval Hurdle Claims

New MarketBeat Followers Over Time

Media Sentiment Over Time

Concert Pharmaceuticals stock logo

Concert Pharmaceuticals NASDAQ:CNCE

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Rigel Pharmaceuticals stock logo

Rigel Pharmaceuticals NASDAQ:RIGL

$18.65 -0.06 (-0.32%)
Closing price 04:00 PM Eastern
Extended Trading
$18.66 +0.02 (+0.08%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Spectrum Pharmaceuticals stock logo

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Urovant Sciences stock logo

Urovant Sciences NASDAQ:UROV

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Verrica Pharmaceuticals stock logo

Verrica Pharmaceuticals NASDAQ:VRCA

$0.65 +0.05 (+7.87%)
Closing price 04:00 PM Eastern
Extended Trading
$0.64 -0.01 (-1.59%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.